Table 1.
Therapeutic ranges of AUC(0–12) and C0 for kidney recipients receiving tacrolimus or cyclosporine.
| Groups | Therapeutic Ranges | |
|---|---|---|
| AUC(0–12) | C0 | |
| 1–5 years (Tacro + MMF) |
120–150 µg/h/L | 4–6 µg/L |
| >5 years (Tacro + MMF) |
120–150 µg/h/L | 3–5 µg/L |
| 1–5 years (Tacro) |
120–150 µg/h/L | 4–6 µg/L |
| >5 years (Tacro) |
120–150 µg/h/L | 3–5 µg/L |
| 1–5 years (CsA + MMF) |
3.05–3.75 mg/h/L | 75–150 µg/L |
| >5 years (CsA + MMF) |
2.70–2.98 mg/h/L | 75–150 µg/L |
| 1–5 years (CsA) |
3.05–3.75 mg/h/L | 75–150 µg/L |
| >5 years (CsA) |
2.70–2.98 mg/h/L | 75–150 µg/L |
CsA—cyclosporine; MMF—mycophenolate mofetil; Tacro—tacrolimus.